Edwards Lifesciences raises full-year outlook after 11.2% Q3 growth
As seen on the 24/7 Wall St. homepage on November 4, 2026.
We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook.
A guidance raise from the structural heart leader lands while Abbott and Boston Scientific push harder into valve repair, and the growth came from every business and region. The $57 billion medtech name is defending share.
Continue ReadingShow less
Edwards Lifesciences CEO Bernard J. Zovighian credited broad-based performance across every business line and every region for the company's confidence in lifting its full-year guidance. That kind of across-the-board strength is harder to dismiss than a single-product beat, and it signals the structural heart franchise is not leaning on one geography or one device category to carry results.
The 11.2% third-quarter growth figure exceeded expectations, which is notable given the competitive pressure Edwards is absorbing. Abbott and Boston Scientific have both been pushing deeper into valve repair, the same structural heart territory where Edwards has long set the pace. Holding above-expectation growth while that rivalry intensifies is the clearest evidence yet that the company is defending its share.
Sponsored
A guidance raise at this stage of the year carries real weight. It tells investors that management sees the remaining quarters as capable of sustaining, not just matching, the momentum built through Q3. For a medtech name of this scale, that level of forward conviction is not offered lightly.
Shares edged up roughly 1% following the quote, a measured reaction that reflects investors digesting what comes next rather than celebrating what already happened. The competitive dynamic with Abbott and Boston Scientific means execution over the next several quarters will matter as much as the Q3 headline.
Sources
Mentioned: EW